R33: Levetiracetam in Early Psychosis
Public ClinicalTrials.gov record NCT04317807. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-week Randomized, Double-blind, Placebo-controlled Trial Investigating the Effects of Levetiracetam in Early Psychosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 12-week study of levetiracetam added to a second generation antipsychotic in early psychosis patients who have been ill for less than 5 years and continue to experience psychotic symptoms despite at least 8 weeks of antipsychotic treatment. Levetiracetam (Keppra) is a medication approved for the treatment of epilepsy; it reduces excessive activity in the brain. This study will test the hypotheses that adding levetiracetam will improve psychotic symptoms that are unresponsive to antipsychotic treatment and will protect the brain from atrophy (volume loss). .
Study identification
- NCT ID
- NCT04317807
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 65 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years to 40 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 26, 2020
- Primary completion
- Mar 31, 2025
- Completion
- Apr 9, 2025
- Last update posted
- May 28, 2026
2020 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NYU Langone Health | New York | New York | 10016 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Early Psychosis trials
Other public records listing Early Psychosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT06774430: Digital Strategies to Advance Help-Seeking Aim 1 and 2 Recruiting
- NCT06774417: Digital Strategies to Advance Help-Seeking - Aim 3 Recruiting
- NCT06740383: Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services Recruiting
- NCT07417904: BRAVE Program to Improve Safety and Reduce Violence Risk in Early Psychosis Not yet recruiting
- NCT04411225: Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04317807, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 28, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04317807 live on ClinicalTrials.gov.